Oncocyte announced that Ronnie Andrews will step down from his role as CEO and as a director of the company’s board of directors effective December 1. In order to ensure a smooth transition effective as of December 2, Joshua Riggs will serve as interim CEO until such time as a new CEO has been identified and retained and Andrews will continue to act a consultant until February 28, 2023. Riggs, who has been Oncocyte’s General Manager, Transplant since July 2022 and was the company’s Senior Director Business Development from August 2020 until September 2022, is a seasoned business development strategist with significant experience working with early and growth-stage molecular diagnostics companies. From January 2016 to July 2020, he was a principal at Bethesda Group, LLC, a boutique consulting group focused on helping small and mid-stage diagnostic companies and investment groups move emerging diagnostic content and platforms to market.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCX:
- Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
- Oncocyte Announces Executive Leadership Changes
- OncoCyte price target lowered to $1 from $1.50 at Piper Sandler
- OncoCyte has engaged advisor to assist in evaluating alternatives
- OncoCyte reports Q3 EPS (8c), consensus (11c)
